ACADIA Pharmaceuticals Inc.

NASDAQ:ACAD

Biotechnology

Healthcare
$17.59 -0.60%

-$0.13 today

Market cap
$3.04B
Beta
0.83
P/E (TTM)
9.7
EPS (TTM)
$2.20
52W Low $19.69High $28.35

Volume 1.45M

Average 1.66M

Income Statement

Follow revenue through to earnings.

Revenue

$1.07B

FY 2025 · Annual

+11.9% YoY

Operating Income

$104.81M

FY 2025 · Annual

-54.6% YoY

Net Income

$391.00M

FY 2025 · Annual

+72.7% YoY

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue484.15M517.24M726.44M957.8M1.07B
Cost of Revenue19.14M10.17M45.73M81.84M89M
Gross Profit465M507.07M680.71M875.96M982.51M
Gross Margin96.0%98.0%93.7%91.5%91.7%
Research & Development239.42M361.58M351.62M303.25M328.8M
Selling, General & Admin396.03M369.09M402.47M488.43M548.89M
Operating Expenses635.44M730.67M754.09M645.16M877.7M
Depreciation & Amortization3.34M2.03M5.55M15.88M11.76M
EBITDA(164.18M)(211.42M)(45.48M)100.16M150.66M
EBITDA Margin-33.9%-40.9%-6.3%10.5%14.1%
Operating Income(170.44M)(223.6M)(73.38M)230.79M104.81M
Operating Margin-35.2%-43.2%-10.1%24.1%9.8%
Interest Income591K6.61M17.23M25.46M31.72M
Interest Expense00000
Other Income / Expenses2.92M10.15M22.34M27.28M34.09M
Income Before Tax(167.52M)(213.44M)(51.04M)258.08M138.9M
Pre-Tax Margin-34.6%-41.3%-7.0%26.9%13.0%
Income Tax Expense351K2.53M10.25M31.62M(252.1M)
Net Income(167.87M)(215.98M)(61.29M)226.45M391M
Net Margin-34.7%-41.8%-8.4%23.6%36.5%
EPS (Basic)(1.05)(1.34)(0.37)1.372.32
EPS (Diluted)(1.05)(1.34)(0.37)1.362.29
Weighted Avg Shares160.49M161.68M163.82M165.72M169.34M
Weighted Avg Shares (Diluted)160.49M161.68M163.82M166.36M171.36M

ACAD Earnings Waterfall · TTM

NASDAQ:ACAD · Revenue to Net Income

Key Ratios

EPS$2.11
Gross Margin68.1%
Net Margin30.9%
P/E Ratio83.4
P/S Ratio13.6

Analysis

$1.2B of revenue converted into $362.2M of net income for the selected period. Gross margin is 68.1% and net margin is 30.9%, showing how much revenue survives after costs and taxes. EPS is $2.11, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 4, 2026
4Statement of changes in beneficial ownershipOct 30, 2026
8-KCurrent reportOct 23, 2026

How much revenue does ACAD generate?

ACADIA Pharmaceuticals Inc. (ACAD) reported $1.07B of revenue in fiscal 2025.

Is ACAD profitable?

ACADIA Pharmaceuticals Inc. (ACAD) reported $391.00M of net income, with a net margin of 36.5%.